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ABSTRACT
This paper discusses the challenges and advantages of implementing Quality by Design (QbD) and Question
based Review (QbR) when developing solid dosage formulations and manufacturing processes for generic
drugs. Formulation and process development of a drug product is challenging due to the inherent variability
of the processes. Regulatory agencies, such as the Food and Drug Administration (FDA) in the USA, demand
a QbD approach when developing formulations and processes for new and existing medicinal products. The
QbD approach is described in the International Conference on Harmonization (ICH) Guidance Q8 (R2). The
regulatory reviewers follow the QbR approach during the review of Chemistry, Manufacturing, and Controls
(CMC), which have also adopted some of the elements of the QbD guidance. A systematic application of
scientific principles for developing the formulations and processes for generic drug products following the
QbD approach is outlined below in three main categories. The categories are product understanding, process
understanding, and control strategy. The concept of predefined objectives, quality risk management, and
CMC considerations together with the prior knowledge are discussed in detail. The discussions and
explanations provided in this paper are based on sound scientific principles, as well as, practical experience
applied to resolve product quality and manufacturing issues. Emphasis is given to streamlining formulation
and process development that complies with current QbD and QbR principles  in order to prevent commonly
cited deficiencies. Examples are provided as guiding tools for generic formulation and process development.
KEY WORDS: Generic formulation development, Quality by Design, QbD, Quality based Review, QbR, product and
process understanding, Chemistry Manufacturing and Controls, CMC
INTRODUCTION
Formulation and process development of drug
products are challenging for the generic
pharmaceutical industry because of the need to
get them quickly to the market because of
inherent process and material variabilities and
cost of development. The inherent variability
associated with formulation and development is
driven by several factors. Some of the factors
are (i) patent expiration of a number of
medicinal products within a short span of time,
(ii) increased competition from  new entrants as
well as generic versions of the innovator drug
products, (iii) enhanced scrutiny by  regulatory*Corresponding author: Manjurul Kader, 11907 Rue Calls,
 Pierrefonds, Quebec, H8Z3K8, Canada, Tel: 647 854 6512, 
 E-mail: manjurul.kader@outlook.com





bodies, (iv) increasingly lower prices due to
government mandated price cuts to make
healthcare more affordable, and (v) existing
patents of drug substances, drug formulations
and their  manufacturing processes. 
The two greatest challenges facing the generic
pharmaceutical industry today are a trend in
decreasing drug prices and increasing regulatory
scrutiny. Regulatory bodies, such as the FDA,
now require the generic pharmaceutical industry
to adopt QbD when developing formulations
and processes for a drug product. ICH Q8 (R2)
Guidance states that QbD “is a systemic
approach to pharmaceutical development and
manufacturing that begins with predefined
objectives and emphasizes product and process
understanding and process control, based on
sound science and quality risk management.”
The question is, how can QbD and QbR be
implemented without impacting time to market
and cost of development? 
The benefits of implementing QbD and QbR
have been discussed previously (1). The
McKinsey QbD Report stated that best practice
in product and process development (PPD)
could increase net profits by up to 20% (2).
PPD directly determines production cost
before and after commercial launch. It accounts
for 15-50% of the total research time and
development (R&D) expenditure. PPD can also
improve overall equipment effectiveness
(OEE), a standard operational performance
measure which is about 35-50% for the
pharmaceutical industry compared to 70-90%
in other comparably regulated industries.
Downtime in the manufacturing processes adds
to production costs. The application of QbD in
PPD ensures a reduction in wasted time
thereby increasing overall profitability. In
addition, the FDA has incorporated some
elements of QbD in the QbR methodology for
CMC for generic drugs (3). 
The required elements for pharmaceutical
development as described in the ICH QbD
Guidance (4) are (a) defining the quality target
product profile (QTPP) based on the route of
administration, dosage form, bioavailability,
strength, and stability, (b) identifying, studying
and controlling potential critical quality
attributes (CQAs) of the drug product, (c)
determining the type and amount of excipients
and their critical material attributes (CMAs), (d)
selecting the appropriate manufacturing
process, (e) establishing the critical process
parameters (CPPs) and linking high risk CMAs
and CPPs to drug product CQAs and its
manufacturability using risk assessment tools,
and (f) defining a control strategy. 
The purpose of the guidance is to ensure a
desired product performance. There are other
elements, such as design space, and process
analytical technology (PAT), which are not
discussed in this paper. Therefore, an increased
level of product and process understanding is
required to fulfil the objectives of the QbD and
QbR approaches. Product and process
understanding are achieved by a systematic
application of scientific principles to
formulations and process design. The question
remains, what does product and process
understanding mean and how can it be
demonstrated?
Product and process understanding is described
in the QbR methodology. Product
understanding is related to the input materials’
(e.g. drug substance, excipients, and container
and closures) critical attributes. The critical
attributes of the input materials are those which
affect drug product performance. Process
understanding is related to process attributes,
which are sometimes influenced by the input
materials and hence affect drug product
performance. The acceptable norms in
demonstrating product and process
understanding are (a) identification of all
possible attributes of the materials and process





Figure 1 QbD approach for generic formulation and manufacturing processes
parameters that could impact the drug product
performance, (b) determination of high risk
attributes of the materials and process
parameters using risk assessment tools, (c)
determination of level, range of the high risk
materials attributes and process parameters, (d)
performing actual trials, and (e) analysis of
experimental data to determine appropriate
range for CQAs, CMAs, and CPPs. Prior
knowledge from developing similar
formulations and processes together with
design of experiments (DoE) can be accepted
as a demonstration of product and process
understanding. Prior knowledge and how it can
be demonstrated is discussed later in this paper.
The QbD concepts, terminology, and
differences between the typical versus QbD
approach have been discussed previously (5, 6).
This paper focuses on the development of
formulations and manufacturing processes for
generic solid dosage forms, as well as, reviews
questions and deficiencies. Analytical method
development is considered outside the scope of
this paper. A schematic of the QbD approach
in developing the generic formulations and
manufacturing process is illustrated in Figure 1.
This paper discusses the techniques with
relevant examples to fulfill the requirements of
the QbD and QbR approaches and the science
behind the required elements. The explanations
provided in this paper are based on practical
experience and approaches applied to resolve
product quality issues with scientific rationale.
The definitions of some important terms used
in this paper are provided below.
DEFINITIONS
AUC (area under the curve) is a method of
measuring the bioavailability of a drug based on
a plot of blood concentrations sampled at
frequent intervals. It is directly proportional to
the total amount of unaltered drug in the
patient’s blood (7). 
Cmax (maximum plasma concentration) is the
peak concentration that a drug achieves in a
specified compartment after the drug has been
administrated and before administration of a
second dose (7). 
Control Strategy is a planned set of controls,
derived from current product and process
understanding that ensures process
performance and product quality. The controls
can include parameters and attributes related to
drug substance and drug product materials and
components, facility and equipment operating
conditions, in-process controls, finished
product specifications, and the associated
methods and frequency of monitoring and
control (4). 
CPPs is a process parameter whose variability
has an impact on a critical quality attribute and
therefore should be monitored or controlled to
ensure the process produces the desired quality
(4).
CQAs is a physical, chemical, biological or
microbiological property or characteristic that
should be within an appropriate limit, range, or
distribution to ensure the desired product
quality (4).





Process robustness is the ability of a process to
tolerate variability of materials and changes of
the process and equipment without negative
impact on quality (4.)
Quality Risk Management is a systematic
approach for assessing, controll ing,
communicating and reviewing risks to the
quality of the drug (medicinal) product across
the product lifecycle (8). Risk based assessment
is proportionate to the level of scientific
understanding of how formulation and
manufacturing process factors affect product
quality and performance, and the capability of
process control strategies to prevent or mitigate
the risk of producing a poor quality product.
QTPP is a prospective summary of the quality
characteristics of a drug product that ideally will
be achieved to ensure the desired quality, taking
into account the safety and efficacy of the drug
product (4).
Tmax is the time after the administration of a
drug when the maximum plasma concentration
is reached i.e., when the rate of absorption
equals the rate of elimination (7).
QbD and QbR approaches together with
commonly cited deficiencies and the concept of
prior knowledge are described as Product
Understanding,  Process Understanding,
Control Strategy and Prior Knowledge
expanded further below.
PRODUCT UNDERSTANDING
The typical components of product
understanding are (i) analyzing the reference
listed drug (RLD) product, (ii) determining the
QTPP, (iii) defining drug product CQAs, (iv)
characterizing the drug product components,
and (v) assessing the risk associated with the
input materials and the drug product. The
components of drug product understanding are
discussed below.
RLD Analysis
Generic drug product development begins with
a predefined objective. The objective is to
develop a product, which is therapeutically
equivalent to the RLD. Therefore, the starting
point for successful development of a generic
drug product is the complete understanding of
the RLD properties. The major components of
the RLD analysis, such as composition,
physicochemical characteristics and its CQAs,
dissolution, and biological properties are
described below with relevant examples.
Composition
Drug product formulation and process
development begins with a description of the
components and composition of the RLD. The
descriptions of the components include
references to the quality standard of each
material and their functional category. The
functional aspect of each material is crucial to
the formulations and process development
rationale. The quantitative/qualitative com-
position of the RLD is available in the
literature, such as in the product monograph,
the label and patents. An example of describing
the components and composition is outlined in
the manufacturing process development
section.
Physicochemical Characterization
Physicochemical characterization of the RLD is
carried out to identify potential pitfalls in the
proposed product. Recent and near the end of
the shelf life batches of the reference drug
product are characterized to understand the
physical and chemical attributes. Analysis of a
near the end of the shelf life batch is critical for
establishing an impurity profile and dissolution,
and for preventing an out-of-specification
(OOS) situation. Typical elements of the
physicochemical characteristics of the RLD are
listed below. These elements are in line with the





presentation titled “Quality Target Product






% BCS (Biopharmaceutics Classification System)
Class
% Tablet shape and dimension 




% Disintegration time (without discs)




% Tablet surface area and porosity 
% Tablet water vapor sorption
% Impurity (A, B, C, D)
% Highest Unknown Impurity
The critical physicochemical attributes of RLDs
are disintegration and dissolution, which are
discussed in the section on RLD dissolution.
Additionally pH, surface area, porosity, and
hygroscopicity of the RLD tablet are typically
analyzed to gain information on the specific
properties of the drug product. For example,
changes in pH can significantly influence the
solubility of some drugs. Therefore, a pH
modifying excipient may be used with free base
or salt to adjust the micro-environmental pH.
The pH in tablets is generally measured using a
pH meter by dissolving the tablet into water.
Tablet surface area and porosity of some drugs
influence dissolution and degradation. Surface
area, morphology, and porosity are critical
attributes for BCS (biopharmaceutical
classification system) Class II and IV drugs as
dissolution is the rate limiting step for such
drugs. Surface area and porosity are generally
analyzed using the BET (Brunauer, Emmett,
Teller) method. The water adsorption/
desorption nature of the drug product and drug
substance is helpful in designing the
formulations and processes of the hygroscopic
and hydrolytic molecules. Water vapor sorption
is a gravimetric technique that measures how
quickly and how much of a solvent is absorbed
by a sample. 
Dissolution 
The dissolution profile of the proposed drug
product must be similar to the RLD. A
discriminatory dissolution test method is used
to demonstrate the similarity between the
proposed drug product and the RLD.
Discriminatory dissolution test methods could
be used to detect from higher to a lower soluble
forms and/or transitions from metastable to a
stable form of a drug substance in a drug
product.  A biorelevant dissolution test is also
performed on a case-by-case basis. The purpose
is to demonstrate in vitro/in vivo correlations
(IVIVC) and to develop in vitro dissolution
specification (10). In vitro/in vivo correlations are
generally accepted for BCS Class II, III and
some BCS Class II drugs. The common factors
associated with dissolution tests are apparatus,
dissolution media, pH of the dissolution media,
solubility and stability of the drug substance in
the dissolution media, and discriminatory
power of the dissolution test method.
In general, United States Pharmacopeia (USP)
dissolution apparatus are preferred for
dissolution testing. The four types of USP
dissolution apparatus (1-4) for testing solid
dosage forms are discussed below.
USP Apparatus 1 is a rotating basket type
apparatus for which the recommended agitation
rate is between 50 and 150 RPM and the
compendial preference is 100 RPM. It is
generally used for testing the dissolution rate of
capsules and tablets. The USP apparatus 1 is
preferred for testing immediate release (IR) and
modified release (MR) dosage forms. The





agitation ranges are usually used for the
development of IVIVCs (11, 12).
USP Apparatus 2 is a rotating paddle type
apparatus for which the recommended agitation
rate is between 25 and 100 RPM and the
compendial preference is 50 RPM. It is
generally used for testing the dissolution of
tablets and capsules. Similarly to the USP
apparatus 1, it is used for testing IR and MR
dosage forms. The agitation ranges are usually
used for developing IVIVCs (11,12). The USP
apparatus 2 is the most preferred apparatus for
developing dissolution test methods.
USP Apparatus 3 is a reciprocating cylinder
bio-dis type apparatus and recommended dip
rate is between 10 and 15 RPM. It is generally
used for testing poorly soluble drugs and MR
dosage forms. The USP apparatus 3 is not
accepted by the Japanese Pharmacopeia.
USP Apparatus 4 is flow-through cell apparatus
which is generally used for testing
multiparticulate dosage forms.
The dissolution media are selected based on the
drug solubility screening. The media should be
capable of dissolving 3 times the drug
substance and must be stable in the media for
at least 24 hours. The recommended pH range
of the dissolution media for IR and MR
formulations is 1.2-6.8 and 1.2-7.5 respectively
(10, 11). Typically, a dissolution test (n=12) is
performed using 2 to 3 dissolution media. The
purpose is to establish the discriminatory power
of the dissolution test method. 
An aqueous medium with a pH range of 1.2 to
6.8 is commonly used for dissolution tests (11,
12) of IR dosages forms. Use of water as a
dissolution medium is discouraged because test
conditions, such as pH and surface tension, can
vary depending on the source of water. In
addition, the pH and surface tension may
change during the dissolution test due to the
influence of the drug substance and excipients.
A dissolution medium of pH 6.8 is used to
simulate intestinal fluid (SIF). A higher pH
(NMT 8.0) is used on a case-by-case basis,
however, a justification is required if using a
higher pH. To simulate gastric fluid (SGF), a
dissolution medium of pH 1.2 is used without
enzymes. On a case-by-case basis, enzymes,
such as pepsin with SGF, and pancreatin with
SIF can be used with justification. For example,
pepsin is used with SGF for dissolution testing
of some gelatin capsule products. It is reported
that storage conditions, formulation as well as
analytical test methods influence gelatin
crosslinking (13). 
Gelatin crosslinking can be caused by extremely
hot and humid storage conditions, intense
ultraviolet (UV) or visible lights. Gelatin
crosslinking is caused by the presence of corn
starch, aldehydes, imines, ketones, saccharides
(glucose and aldose sugar) calcium carbonate,
hydrogen peroxide, and dyes (FD&C Red No.
3 or 40 and Blue No. 1) in the formulation or in
the empty gelatin capsules. A barrier film is
formed during storage due to gelatin
crosslinking. The barrier film prolongs the
disintegration time and a subsequent decrease
in dissolution rate. Pepsin in the dissolution
medium breaks down the crossed-linked barrier
film quicker than acid alone, and hence permits
the release of the drug. Therefore, USP <711>
(Dissolution) recommends the addition of an
enzyme (e.g. pepsin) to the dissolution medium.
However, it is required to demonstrate that a
decrease in dissolution is directly related to
crosslinked gelatin shells rather than the
degradation of the drug product. A surfactant,
such as sodium lauryl sulfate (SLS) can be used
for water insoluble or sparingly water soluble
drug products. However, a justification for the
need and the amount of the surfactant is
required.
The dissolution test of highly soluble (largest
dose dissolved in # 250 ml of water over a pH





Figure 2 pH dissolution profiles of a brand named Risedronate Sodium 150 mg tablets (batch XYZ) in
USP Purified Water, 0.1N HCl, and 0.05 M Phosphate Buffer pH 4.5 and pH 6.8.
range of 1.2 – 6.8) and highly permeable (extent
of absorption is > 90%) drugs (classified as
BCS Class I) could be replaced by a simple
disintegration test. The ICH Guidance (14) also
permits the use of a disintegration test as a
surrogate for the conventional compendial
dissolution test provided that (i) the drug is
highly soluble, (ii) the intrinsic rate of
solubilization is rapid, and (iii) the overall drug
release rate is dominated by cohesive properties
of the formulation. However, a justification for
the selection of dissolution versus a
disintegration test, as well as, the development
and suitability of the chosen test is required.
This is generally carried out by establishing a
relationship between disintegration and
dissolution. The relationship proves that
disintegration is more discriminating than
dissolution and therefore a simple
disintegration test could replace the dissolution
test.
Drug substance solubility, formulations and
process variables often influence the dissolution
of hydrophobic and poorly water soluble drugs
(BCS Class II and IV). The typical formulations
and process variables are excipient attributes
(hydrophilic/hydrophobic), levels and grades,
tablet hardness, surface area and porosity of the
drug product. In addition to these factors, the
physiological conditions of the gastrointestinal
tract (GI) affect drug product dissolution (15).
Therefore, a discriminatory dissolution test
method is used to analyze the proposed and
referenced drug product. The purpose is to
assess the impacts of the excipients CMAs and
levels, and tablet hardness on dissolution rate.
An example of the RLD dissolution study is
discussed below.
The dissolution study for an RLD (e.g. a brand
named Risedronate sodium 150 mg tablet, batch
XYZ, expiry date month/year of the USA
market) was carried out across the four
physiological pH ranges. The media used were
USP purified water (deaerated), 0.1N HCl, 0.05M
phosphate buffer pH 4.5 and pH 6.8. During the
study, USP Apparatus 2, using an agitation rate
of 50 RPM and a volume of 900 ml dissolution
medium was used. The USP dissolution
specification for Risedronate sodium is NLT
80% (Q) dissolved in 30 minutes for tablets
labeled to contain at least 75 mg. The drug
release profile of the RLD in these four
dissolution media is illustrated in Figure 2.
The RLD (i.e., the brand named drug) exhibits
very rapid dissolution profiles, $ 85% of the
drug substance dissolved within 15 minutes, in
water. Therefore, the dissolution profile of the





proposed generic drug product considered
similar and no mathematical evaluation (i.e., f2
calculation) is required. 
Biological Properties
The RLD biological properties must be
described according to clinical and
pharmacokinetics {ADME: absorption (AUC,
Cmax, Tmax), distribution, metabolism, and
elimination}. The bioequivalency of the drug
product depends on the absorption site which
for oral dosage forms is the GI tract. The
criticality of the Cmax and AUC depends on the
solubility of the drug (based on BCS Class). 
Drugs classified as BCS Class I (High
solubility/High permeability, amphiphilic in
nature) are well absorbed in the GI tract.
However, the absorption of such drugs is
controlled by gastric emptying. Highly
permeable drugs are rapidly absorbed in the GI
tract. Therefore, Cmax is the critical in vivo
parameter for such drugs and is indicative of
overall AUC. Compounds belonging to BCS
Class I are eligible for biowaiver, if the
dissolution of the compound is >85% within
30 minutes at pH 1.2 to 6.8 when tested using
USP dissolution apparatus 1 without adding
lecithin, bile salts or enzymes in the dissolution
media.
The absorption of BCS Class II (Low
solubility/High permeability, lipophilic in
nature) drugs in the GI tract is good and
controlled by dissolution. Cmax  is the critical in
vivo parameter for such drugs. According to the
World Health Organization (WHO), certain
BCS Class II compounds are eligible for
biowaiver, if the compound is a weak acid with
a dose:solubility ratio of <250 ml at pH 6.8,
and the dissolution is > 85% within 30 minutes
at pH 6.8 tested at 75 RPM. However, in the
USA the FDA and the EMA (European
Medicines Agency) in Europe do not allow for
a biowaver for BCS Class II drugs.
The absorption of BCS Class III (High
solubility/Low permeability, hydrophilic in
nature) drugs in the GI tract is limited and
controlled by permeability. Cmax and AUC are
the critical in vivo parameters for such drugs.
BCS Class III compounds are eligible for
biowaiver if the compound dissolves within 15
minutes at pH of 1.2 to 6.8 tested at 75 RPM.
The absorption of BCS Class IV (Low
solubility/Low permeability, hydrophobic in
nature) drugs in the GI tract is poor. Cmax and
AUC are the critical in vivo parameters for such
drugs.
The physiology of the GI tract, for example
pH, residence time, and various bile salts can
influence the biological properties (e.g. Cmax and
AUC) of the drug molecule. The small intestine
has a high concentration of bile salts with a
large surface area due to its villi and micro-villi
structures. This area serves as the primary site
for drug absorption. Therefore, the knowledge
of where in the GI tract the drug is absorbed
facilitates formulation design. In addition, it is
useful to understand the impact of food on
drug absorption, bioavailability (BA) and
bioequivalence (BE) when developing the
formulation. The dissolution of weakly basic
drugs is slower at a higher pH because more
drugs exist in its unionized form. On the other
hand, weakly acidic drugs dissolve faster at
higher pH due to the fact that more drugs exist
in its ionized form. Therefore, meals that
elevate gastric pH can decrease the dissolution
of a weak base by increasing the proportion of
drug existence in its un-ionized state. For
example, Indinavir, a weak base with pKa
(dissociation constant) of 3.7 and 5.9 forms
precipitate when gastric pH is elevated during a
meal. The formation of precipitates causes a
significant reduction in AUC and Cmax values of
the Indinavir in fed versus fasted human
subjects (16). The biological properties of the
RLD are generally available in the product
monograph and/or in literature. 






The QTPP is a prospective summary of the
quality characteristics of a drug product and
forms the basis of the development design. The
RLD analysis determines the QTPP of the
proposed drug product. An example for
determining the drug product QTPP (17) is
outlined in Table 1, which is in line with the
presentation entitled “Quality Target Product
Profile with Examples (9).
Table 1 Quality Target Product Profile (QTPP)

























































Situations in which the
drug might be
contraindicated.
Same as the RLD.
Use in specific
populations
Not to specific group.
No plan to study
the drug in a
specific














IR = Immediate release
Determining Drug Product CQAs
The QTPP defines the critical and non-critical
attributes of the proposed drug product. The
formulations and/or process variables can
potentially alter the critical quality attributes of
the drug product. An example of determining
the drug product CQAs is presented in Table 2.
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NMT 0.8 % @ 100
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NMT 1.2% @ 200
rev.

































Characterizing drug product components
The drug product components, such as drug
substance and excipients are discussed below.
Drug substance 
The ICH Guidance requirement is to identify
and discuss the physicochemical and biological
properties of the drug substance and their
influence on drug product performance and its
manufacturability (4). The required QbD





elements for drug substance are (a)
physicochemical and biological properties, (b)
degradation pathway (e.g. intrinsic stability), (c)
chemical reactivity, and (d) risk assessment. 
Some of the deficiencies in drug substances as
cited by the FDA (18) are (i) multiple
polymorphic forms are reported in the
literature, provide the form used and a suitable
control to ensure consistency in the drug
substance, (ii) include a control for the relevant
enantiomer and diastereomers if the drug
substance is chiral and the enantiomers show
differences in pharmacological effect and/or
safety, and (iii) justify the specification for the
full range of particle size distribution (PSD).
Alternatively, it is possible to show that the
PSD is not critical to the manufacturing process
and drug product performance. 
The physicochemical and biological properties
of the drug substance usually examined include
aqueous solubility (as a function of pH), water
content, particle size, crystal properties (e.g.
polymorphism), biological activity, and
permeability. Other physicochemical and
mechanical properties of the drug substance
include melting point, particle shape, surface
area, porosity, pKa, partition coefficient,
stereoisomers, chemical stability, flowability,
and compressibility. If they are interrelated
some of these properties will be considered in
combination. An explanation is required if a
property is not included. For example, pKa may
not be listed because there are no ionizable
groups in the chemical structure. The product
development report usually describes the
polymorphism, solubility, and particle size of
the drug substance.
Physicochemical and mechanical properties of the drug
substance
Some of the physicochemical and mechanical
properties of the drug substance and their
influence on drug product performance and its
manufacturability are discussed below with an
example.
Polymorphism 
Polymorphs of a drug substance that are
generally recognized are amorphous, crystalline,
hydrate and solvate (19). However, polymorphs
refer to crystalline structure of a molecule. By
definition, an amorphous material is not
crystalline. Hydrates and solvates may, or may
not, be crystalline and could have their own
polymorphs. The physicochemical properties,
for example, solubility, hygroscopicity, particle
shape, density, flowability, and compactibility of
different polymorphs of a drug substance are
different. Therefore, polymorphic forms of the
drug substance influence the performance of
the drug product and its manufacturability. 
The thermodynamically most stable polymorph
should be chosen for the formulation to ensure
optimum product performance and
manufacturability. A thermodynamically stable
polymorph is chemically stable and has the least
potential for conversion to another polymorph
when exposed to a range of manufacturing
processes, such as drying, mill ing,
micronization, wet granulation, spray-drying,
and compaction (20).  However, occasionally, a
metastable form is preferred over the stable
form, since they have better solubility, and
bioavailability/ bioequivalency. A metastable
form has a high energy state, low melting point
and high aqueous solubility. 
Water in pharmaceutical hydrates is generally
present in three different form, for example,
residing in isolated lattice sites, in the lattice
channel sites, which are also referred to as
channel water and in the ion-coordinated sites
(20, 21). In isolated lattice sites, water molecules
are in contact with the drug molecule and
therefore, isolated from other water molecules.
Channel water is in contact with other water
molecules of adjoining unit cells along an axis





of a unit cell and is mobile in nature. Therefore,
channel water may migrate into and out of the
crystal lattice as a function of ambient humidity.
Ion-coordinated water participates in an ion
water bond, which is usually stronger than
hydrogen bonds present in the molecule. The
removal of isolated lattice water generally
compromises the crystal integrity. In contrast,
crystal integrity remains relatively intact upon
removal of channel water (21). However, upon
the removal of channel water from some drug
substances e.g. Risedronate Hemipentahydrate,
the crystal integrity has been reported to be
compromised. The hydrate, depending upon
the nature of the water may, or may not, change
over time with ambient humidity, temperature,
or other drug product manufacturing and
storage conditions (22). Therefore, the
metastable polymorph or pharmaceutical
hydrate requires special attention during the
formulation design regarding the selection of,
for example, excipients, as well as, the selection
of the manufacturing processes. The influence
of polymorphic forms on the performance of
the drug product and its manufacturing
processes are discussed below.
Solid state phase conversion (re-crystallization)
of amorphous or metastable drug substances
during manufacturing processing and/or
storage has been observed. For example, a
roller compaction process can influence the
degradation of acetylsalicylic acid, and milled
Carbamazepine anhydrate converts to dihydrate
at least four times faster than the unmilled
material during a wet granulation process (23). 
Mechanical treatments, such as milling, tend to
accelerate the kinetics of dehydration by
generating surface defects and local heating
which causes phase conversion. 
Phase conversion of a drug substance may take
place immediately or, over time, during storage,
at accelerated conditions (40ºC/75% RH). This
is a common occurrence for amorphous
materials.  Drug substance conversion was
reported for an IR formulation containing a
highly soluble drug (24). The drug content in
the formulation was low (# 2 mg). The product
was manufactured by wet granulation. The drug
substance was dissolved during the wet
granulation due to low drug content and high
solubility. The completely dissolved drug
substance converted to an amorphous form
during the drying cycle. The phase conversion
of the drug substance caused a loss in potency
and an increase in related substances at
accelerated storage conditions. The extent of
conversion generally depends on the relative
stability of the polymorphs, kinetic barriers to
phase conversion, and applied stress (25). 
Drug substance phase conversion, however, is
generally not a serious concern provided that
the conversion occurs consistently as part of a
validated manufacturing process where critical
manufacturing process parameters are well
understood and controlled, and where drug
product BA/BE has been demonstrated (19). 
Drug product stability is affected by various
other factors, including the formulation,
manufacturing processes and packaging.
Therefore, stability is an important quality
parameter. The effect of polymorphism on the
drug product manufacturing process also
depends on the formulation and the
manufacturing processes (26). For example, the
impact of the drug’s physical and mechanical
properties on direct compression for low or
high drug content formulations can be
significant compared to dry granulation.
Therefore, paying close attention to the drug’s
polymorphism is critical as it is related to the
manufacturing processes.
If different polymorphic forms are known, it is
required to specify which polymorphic form
was chosen and provide supporting evidence
for the claim. The identification of the
polymorphic form is usually determined using 
different analytical methods, for example, using





a Fourier Transform Infrared Spectroscopy
(FTIR). It collects simultaneously high spectral
resolution data over a wide spectral range and
measures how well a sample absorbs light at
each wavelength). X-ray Powder Diffraction
(XRPD) is a rapid analytical technique primarily
used for phase identification of a crystalline
material. Differential Scanning Calorimetry
(DSC) determines where the energy of a sample
is absorbed or released as it is heated, cooled,
or held at a constant temperature.
Thermogravimetric Analysis (TGA) measures
the change in weight of a sample as it is heated.
Information on drug substance polymorphism
is generally available in the Drug Master File
(DMF) and/or in the literature. An example of
the selection of a polymorphic form is given
below.
A drug substance such as Carbamezepine is
known to exhibit polymorphism and four
anhydrous polymorphs and a hydrate, as well
as, other solvates have been reported in the
literature (27, 28, 29, 30). The four polymorphic
forms of Carbamezapine have been identified
through XRPD analysis (27). Among the four
polymorphs, Form III is the most stable form
at room temperature, and is therefore 
commonly used in tablet formulations (31). The
manufacturing process is a direct compression/
dry granulation process and is not expected to
cause phase conversion during processing.
Therefore, Form III was chosen for
development, and was expected to be stable
throughout its shelf life under normal
environmental conditions. The XRPD data of
the drug substance confirmed that the
polymorph was Form III.
Solubility
Drug substance solubility is often referred to
according to its BCS Class. The solubility of the
drug substance influences the selection of the
excipients and drug product manufacturing
process, stability, and dissolution testing design.
Several factors, for example, polymorphism
(crystalline form), pKa, lipophilicity and high
melting point of the drug substance, lack of
solute-solvent interaction, changes in pH, fluid
contents, and motility, as well as, the residence
time in the GI tract influence the solubility and
in vivo dissolution of an oral solid dosage forms.
For example, a drug substance with an aqueous
solubility of <100 μg/ml is reported to present
dissolution and absorption limitations (32).
Therefore, solubility screening of the drug
substance is a pre-requisite of the formulation
and process development, and for any
application for a biowaiver. Solubility
information of the drug substance is available
in the literature, for example, in the Martindale,
the Extra Pharmacopeia, the Merck Index,
Florey’s Analytical drug profiles and on the
internet (aqueous solubility is available on
Medline®). 
However, there are concerns for using the
solubility information from the literature or the
internet because the reported solubility data is
generally based on using water as the
dissolution media at room temperature and at
one pH only. Therefore, it is essential to
determine the drug substance solubility
experimentally. Solubility screening is
performed using multiple media, such as, acid
and buffer. The media usually  represents all
physiologically relevant pH ranges, for example,
pH 1.1, pH 2-3, pH 4-5, pH 6.8, and pH 7.5 at
37ºC. To determine the dose:solubility ratio, the
highest single dose strength is divided by the
solubility of the compound over the pH range
of 1.1 to 7.5 at 37°C. The drug substance is
considered “highly soluble,” if the
dose:solubility ratio is <250 ml.  The reason for
comparing the solubility < 250 ml or > 250 ml
is that typically, 250 ml of fluid is present in the
upper GI-tract when administering the drug in
a fasted state. The goal is to determine the
optimal solubility and stability of the drug
substance and to meet the FDA BCS
classification system (33). The solubility
screening decision tree is illustrated in Figure 3.




Figure 3 Solubility screening diagram
The solubility in media with different pH also
indicates the pH dependent release nature of
the drug substance. The solubility information
guides the selection of excipients and
manufacturing processes together with the
stability of the drug substance. For example,
Poloxamer 470 (a nonionic triblock copolymers
composed of a central hydrophobic chain of
polyoxypropylene flanked by two hydrophilic
chains of polyoxyethylene), Meglumine (an
amino sugar derived from sorbitol with pKa
value of 9.60) is used as a solubilizing agent for
poorly water soluble drugs, and potassium
bitartrate (the potassium acid salt of tartaric
acid) is used as a buffering agent to ensure
optimal release of the pH dependent drug
substance.  An example of aqueous solubility as
a function of the pH of a drug substance is
shown in Table 3.
Particle size and particle size distribution
A discussion about the drug substance particle
size is mandatory irrespective of the impact on
the drug product performance and its
manufacturability. The criticality of the drug
substance particle size depends on (i) drug
substance solubility, drug product dissolution,
and bioavailability/bioequivalence (ii) dosage
strength (iii) drug content in the formulation
and (iv) manufacturing process, such as, direct
compression >dry granulation >wet granulation.
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Particle size and its distribution influence the 
dissolution and absorption (Cmax and AUC) of 
the drug product, as well as, its manufac-
turability. For example, Cmax and AUC of a drug 
product containing a drug substance with 100 
μm particle size were significantly lower 
compared to the <50 μm (34). Particle size is 
indicative of compressibility and flowability i.e., 
flow and cohesiveness. Therefore, particle size 
usually impacts quality parameters, such as assay 
and dosage uniformity in formulations with a 
low drug content, as well as, the compression 
force of formulations with a high drug content. 
The particle size of a cohesive/milled/
micronized drug substance is of greater concern. 
For example, the mean particle size of the 
micronized Griseofulvin has been reported to 
increase during the com-paction process based 
on drug loading (35). The surface area of a 
particle decreases with increasing particle size 
leading to a decrease in the dissolution rate. In 
addition to an increase in particle size, the 
author experienced excessive wafer build up in 
the granulation chamber during dry 
granulation (roller compaction) process of a 
micronized drug substance.
Therefore, for some drugs, particle size 
specification and its test method is a mandatory 
requirement. In general, laser diffraction, image 
and sieve analysis techniques are employed to 
examine the particle size of a drug substance. 
However, different particle sizes have been 
obtained for a specific batch when analyzed 
using different techniques. In addition, 
different particle sizes can be obtained based on 
the method used for measuring the particle size. 
For example, different particle size are obtained 
for a specific batch when analyzed using wet or 
dry methods by a Malvern particle size analyzer. 
Therefore, it is required to use validated test 
method to analyze particle size. Particle 
fragility, nature of agglomeration and particle 
habits of the material influence the selection of 
particle size test method.  An  example   of  drug 
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Table 3 Aqueous Solubility
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>1 g/ml Very soluble 0.1 N, HCl, pH = 1 1.0 47.2 mg/ml
100-1000 mg/ml Freely soluble 0.05 N HCl, pH = 2 1.7 49.2 mg/ml
33.3-100 mg/ml Soluble 0.15 M acetate buffer, pH = 4 3.7 56.8 mg/ml
10-33.3 mg/ml Sparingly soluble 0.15 M phosphate buffer, pH = 6 5.8 60.8 mg/ml
1-10 mg/ml Slightly soluble 0.15 M phosphate buffer, pH = 8 7.8 56.0 mg/ml
0.1-1 mg/ml Very slightly soluble 
<0.1 mg/ml Practically insoluble 
a Refers to the pH of aqueous media following addition of drug substance.
b Solubility measures were carried out on polymorphic Form I (the most stable form)
Note: hypothetical values are used for dose/solubility calculation. 
The calculated dose/solubility volume:  32 mg (highest strength) ÷ 47.2 mg/ml (minimum concentration of drug) = 0.68 ml. Based on the
BCS Classification system the drug is highly soluble as the dose/solubility volume is less than 250 ml. Considering the strength (low and
high), a drug substance could be classified as high soluble or low soluble, for example, Acyclovir 200 mg tablet belongs to BCS class III
(high solubility - low permeability), whereas Acyclovir 800 mg tablet belongs to BCS class IV (low solubility - low permeability). 
substance particle size discussion is outlined
below.
When the water solubility of a drug substance
(e.g. Captopril) is 160 mg/ml at 25°C (CAS
62571-86-2), it is categorized as a highly soluble
drug (BCS Class III). The drug content in the
formulation is 27.0% W/W. The highest dosage
strength is 100 mg tablet. The manufacturing
process is dry granulation. The particle size of a
highly soluble drug is not critical to the drug
product performance (14). Therefore, the
particle size specification of the drug substance
(e.g. Captopril) is not proposed based on the
drug content in the formulation, manufacturing
process (dry granulation), and particle size of
the dug substance will not be controlled during
routine release test. 
Permeability
The permeability of a drug substance influences
its absorption. Information on permeability for
some drug substances can be found in the
literature, e.g.,, the Martindale, the Merck Index
and Florey’s Analytical drug profiles and on the
internet (permeability or bioavailability is
available on Medline). A drug substance is
considered “highly” permeable, if the
permeability is >90%, measured in
humans/animals or a suitable cell line (e.g.,
Caco 2 cells). However, determination in Caco
2 cells is only applicable to passively absorbed
substances and is used for additional
confirmation. Permeability data from humans is
preferred and animal data is only used if no
other data can be found. The probable reasons
for below 90% bioavailability are degradation in
the GI-tract, first pass effect, solubility limited
bioavailability, and poor absorption. 
Lipinski’s “The Rule of 5” can be used to
predict the permeation of a drug substance.
‘The Rule of 5' predicts that poor absorption or
permeation of a drug substance is more likely,
when (i) there are more than 5 H-bond donors,
(ii) there are more than 10 H-bond acceptors,
(iii) the molecular weight is greater than 500
g/mol, and (iv) the Log P (Clog P) is greater
than 5 (or Mlog P > 4.15) (36). An example of
the drug substance permeability discussion is
provided below.
A drug substance, e.g., Clopidogrel bisulfate has
2 H-bond donor and 8 H-bond acceptor. Its
partition coefficient, Log P is 3.89 in
octanol/water, pH 7.4 at 25°C and it has a
molecular weight of 419.90 g/mol (37).
Therefore, according to “The Rule of 5” the
permeability of Clopidogrel bisulfate is good.





However, following an oral administration, the
bioavailability of Clopidogrel bisulfate is
reported to be about 50% due to its poor water
solubility (38).
 
Water content and hygroscopicity
It is expected to include a test (e.g. Karl Fischer
titration) for water content when appropriate.
Water exists as bound and free water in a
molecule. Generally, the free water associated
with the drug molecule and excipient can
influence dissolution, stability (chemical
degradation e.g., hydrolysis), pow-der flow,
manufacturability and microbial growth.
Typically water is not a reactant except in ester
hydrolysis, however, it accelerates most
reactions by bringing the molecules together
due to an increase in plasticity and molecular
mobility in the system. Highly soluble and
highly hygroscopic drugs have a tendency to
change polymorphic forms during storage at
ambient conditions. A partial change in the
polymorphic form (e.g. crystalline to
amorphous) generally causes faster dissolution.
Tablets and excipients in the formulation are
examined using a XRPD method to confirm
the change in polymorphic form, if any. The
acceptance criteria for water content in such
drugs are usually justified by the effects of
hydration or water absorption. In some cases, a
loss on drying analysis is also adequate. Drug
substance hygroscopicity is usually used to
justify the selection of the excipients grade,
level, and manufacturing process together with
the packaging. The hygroscopicity of the drug
substance is generally analyzed using a dynamic
vapor sorption (DVS) method and is available
in the DMF (drug master file) and/or in the
literature. 
Flowability
Drug substance flowability influences blend
uniformity (BU), uniformity of dosages unit
(DU), assay, and granulate compressibility. The
flowability property is used to justify excipient
selections and manufacturing processes. For
example, direct compression is selected based
on the measured angle of repose (AoR is < 30°)
and the compressibility index (CI is <10%) of
the drug substance and drug content (i.e., 40%
W/W) in the formulation. Therefore, no adverse
impact on the drug product quality attributes
and its manufacturability is anticipated.
Compactability
Together with other factors e.g., formulation
composition and compression press speed,
drug substance compactability influences
compression force and tablet hardness. Drug
substance bulk density is one of the indicators
for compactability. Compactability is critical for
high drug content formulations especially when
compressibility of the drug substance is poor or
moderate. 
The physical properties of the drug substance
have the least impact in a wet granulation.  The
physical and mechanical properties of the drug
substance are often masked during the wet
granulation process (19).
DS Degradation Pathways: Forced Degradation/
Stress Testing
It is required to describe the degradation
pathways of the drug, generally demonstrated
through forced degradation studyes/stress
testing. A stress test is performed in both
solution and solid state for a specific storage
time or until a certain degradation is observed.
The purpose of such a test is (i) to demonstrate
the intrinsic stability of the drug substance, (ii)
to identify environmental factors (ambient
temperature, humidity, light) and oxygen
affecting the stability of the drug product,  (iii) 
to determine the potential degradates and assess
if they can be formed during manufacture or
storage of the drug, (iv) to validate the stability
indicating power of the analytical method, and
(v) to justify the selection of primary packaging





material that protects the drug product during
storage and transportation.
The four main degradation mechanisms are
hydrolytic, oxidative, heat, and photolytic
degradation. Therefore, typically the drug
substance is subjected to these conditions
during forced degradation studies. The
preferred level of degradation depends on the (i)
suitable reagents, (ii) concentration of the
reagents such as acid, base, or oxidizing agent,
(iii) test conditions e.g. varying temperature and
humidity, and (iv) length of exposure. During
stress testing, degradation is controlled to a
desired level to ensure that the drug substance is
not subject to over- or under- stressing. Over-
stressing a sample may lead to the formation of
secondary degradants that would not be seen in
formal shelf-life stability studies and under-
stressing may not serve the purpose of stress
testing. Therefore, a generic approach for stress
testing is applied to achieve purposeful
degradation that is predictive of long-term and
accelerated storage conditions, which is between
5-20% degradation (39, 40, 41, 42). The 5 – 20%
range covers the generally permissible 10%
degradation for small molecule drug products.
The typical stability limits for small molecule
drug product is 90 to 110% of the label claim
(43). Generally, 10% degradation is preferred by
some pharmaceutical scientists to validate the
analytical method for small drug molecules. The
stress conditions are selected based on prior
knowledge of a compound. For instance, low
concentration of a base is generally used for a
compound containing an ester group as the
compound is very labile to base hydrolysis. The
samples are analyzed at different time intervals
as it generally provides information on the
progress of degradation and help to distinguish
primary degradants from secondary ones.
Acid and base hydrolysis
Acid and base hydrolytic stress testing are
carried out for drug substances and drug
products in solution at ambient temperature or
at elevated temperatures. The selection of an
acid or a base and their concentration depends
on the stability of the drug substance. The drug
substance solution is subjected to various pH
values e.g., 2, 7, 10–12 at room temperature for
two weeks or up to a maximum of 15%
degradation (40) to assess the hydrolytic
degradation. Typically, hydrochloric acid or
sulfuric acid at a concentration of 0.1 M to 1 M
for acid hydrolysis and sodium hydroxide or
potassium hydroxide at a concentration of 0.1 M
to 1 M for base hydrolysis is used (43). For
lipophilic drugs e.g., thiopental, inert co-
solvents are generally used to solubilize the drug
substance. The selection of cosolvent depends
on the functional groups present in the drug
molecule.
Oxidation
Oxidative degradation is complex. Hydrogen
peroxide is used predominantly for oxidation
degradation tests because it mimics the possible
presence of peroxides in the drug and/or
excipients. Other oxidizing agents such as metal
ions, oxygen and light are also used. The
selection of an oxidizing agent, its
concentration, and conditions depends on the
drug substance. Typically the drug substance
solution is subjected to 0.1%-3% hydrogen
peroxide at neutral pH and room temperature
for seven days or up to a maximum of 20%
degradation (42). Metals ions e.g., iron and
copper are found in some drug substances and
some excipients. Therefore, metal ions are
added to the solution of the drug substance to
determine whether the drug substance will be
catalytically oxidized or not. Oxidative
degradation influenced by light is discussed
below in the photostability section.
Heat
Thermal stress testing e.g., dry or wet heat is
generally more strenuous than recommended in
the ICH Q1A accelerated testing conditions.
Samples of solid-state drug substances and drug





products are exposed to dry or wet heat,
whereas liquid drug products are exposed to dry
heat. Generally, the effect of temperature is
studied in 10°C increments at 75% or greater
relative humidity (44). In the event that the
stress conditions produce little or no
degradation due to the stability of a drug
molecule, it is required to ensure that the stress
applied is in excess of the energy applied by
accelerated conditions (40°C for 6 months)
before terminating the stress study.
Photostability
Testing photostability is an integral part of stress
testing, especially for photolabile compounds.
The recommended conditions for photostability
testing are described in ICH Q1B Photostability
Testing of New Drug Substances and Product
(45). Samples of a solid/liquid drug product, are
exposed to a minimum of 1.2 million lux hours
and 200 watt hours per square meter light. The
same samples are exposed to both white and
UV light. The temperature is controlled to
minimize the effect of temperature changes
during exposure. The light-exposed samples are
examined for any changes in physical properties
e.g. appearance, clarity, color of solution, and
for assay and degradants. The information is
used to specify the appropriate storage
conditions on the container  labels.
Understanding common degradation pathways
helps in designing stable formulations and
processes and to avoid OOS situations. A
discussion about the common degradation
pathways (e.g. hydrolysis/thermolytic,
oxidation, and photolytic) is not required.
However, the three common degradation
pathways of the drug substance or drug product
are briefly discussed below.
 
Hydrolysis
Hydrolysis accounts for the majority of reported
drug degradations. Hydrolysis is common for a
broad category of organic molecules derived
from weak functional groups such as carboxylic
acids. Moisture, temperature, and pH may
greatly impact the rate of hydrolysis. Drug
substances containing functional groups such as
amide (Acetaminophen, Oxazepam), carbamic
ester (Loratidine), lactone (Warfarin), imide
(Barbiturates), acetal (Erythromycin), imine
(Diazepam, Oxazepam) are susceptible for
hydrolytic degradation.
Oxidation
Oxidation reactions are often catalyzed by
oxidizing agents such as peroxides, metals,
atmospheric oxygen, light, and free-radical. The
reactive impurities in excipients play a key role
in oxidation either as a primary source of
oxidants, trace amounts of metals, or other
contaminants. Three primary mechanisms for
oxidative degradation are nucleophilic and
electrophil ic,  electron transfer, and
autoxidation. Peroxides are a common impurity
in many excipients, such as Povidone,
Crospovidone, Hydroxypropylcellulose (HPC)
etc. Nucleophilic and electrophilic oxidation is
generally initiated by the peroxides present in
the drug substance and in the excipients.
Electron transfer oxidation is typically mediated
by the transition metal ions presents in the
excipients. Oxidizing agents can produce free
radicals in the presence of atmospheric oxygen
and light. The free radicals then react with
oxygen to form peroxy radicals. The peroxy
radicals then react with the oxidative substrate
to yield further complex radicals affecting the
stability of the drug product. A free radical often
initiate chain reaction called autoxidation, which
could be autocatalytic and non- Arrhenius.
Photolytic
Drug substances containing functional groups
such as carbonyl, nitro-aromatic, aryl, vinyl,
thiol, or halogens are susceptible for photo
labile degradation (46). Photo labile degradation
is also influenced by the intrinsic
photosensitivity of the counter ions present in





the salt form. Aromatic (toluenesulfonic acid)
and/or carbonyls (oxalic acid) counter ions
shows higher photo degradation compared to
non-aromatic counter ions (47). The
explanation is that oxalic acid, the carbonyl
counter ions and toluenesulfonic acid, the
aromatic counter ions have the higher tendency
for photo degradation due to the inherent
property. Hydrated salts are more susceptible to
photo labile degradation compared to their
anhydrous counterparts. Anhydrous salts
containing aromatic/carbonyl counter ions are
also susceptible to photo labile degradation.
Solid-state photo degradation of amlodipine
camsylate is lower compared to that of
amlodipine besylate (48). The photostability of
prazosin salts are prazosin hydrochloride
anhydrous >prazosin camsylate anhydrous-
prazosin-free base >prazosin hydrochloride
polyhydrate >prazosin tosylate anhydrous




Generally, excipients facilitate the release of the
drug substance, as well as, stabilize it against
degradation. However, excipients can also
accelerate the degradation of the drug product.
The interaction between the drug substance and
excipients influences the instability and
bioavailability/bioequivalency of the drug
product. The reactive impurities of the
excipients as well as the moisture content of the
drug substance and excipients often influence
the instability of the drug product. Some of the
known incompatibilities between the excipients
and drug substance are Meglumine with
Glipizide (50) and Magnesium Stearate with
Clopidogrel (51). Therefore, regulatory bodies
require evidence of compatibility between the
drug substance and excipients.
Typically, the binary mix of the drug substance
and excipient are analyzed to examine the
chemical reactivity between the drug substance
and excipients. The binary mix of the drug
substance and the excipient is stored at different
conditions, such as non-stress, thermal, heat and
humid, and light. After the defined time, the
stored sample is analyzed using a stability
indicating test method to determine the percent
impurities and remaining potency. The common
methods to examine the chemical reactivity are:
(i) chromatographic analysis e.g. HPLC, (ii)
DSC, and (iii) TGA. However, an orthogonal
confirmatory technique is required with DSC to
determine the chemical reactivity. Sometimes
the information from literature is used to justify
chemical reactivity between the drug substance
and excipients instead of performing the
experiment.
Determining DS critical material attributes (CMAs)
The critical attributes of a drug substance are
generally identified by their physicochemical and
mechanical properties, intrinsic stability, and
chemical reactions with the excipients. The
typical critical attributes of the drug substance
affecting drug product CQAs and its
manufacturability for explicit tracking in risk
assessment are: (i) polymorphism, (ii) solubility
(BCS Class), (iii) particle size, (iv) intrinsic
stability, and (v) water content and
hygroscopicity.
Excipients
Excipients affects critical attributes of a drug
product such as bioavailability and stability, as
well as, manufacturability. Mannitol may
influence drug absorption and thus the
bioavailability of a drug product. The probable
explanation is that Mannitol influences gastro-
intestinal motility due to contraction and can
decrease the transit time in the small intestine
which may impact drug absorption and thus its 
bioavailability (52, 53). Excipients such as
surfactant (Poloxamer) and polymers
(Povidone/Polyvinylpyrrolidone) can impact
the metabolizing cytochrome p-450 enzymes.





The requirements for excipients as stated in the
ICH QbD Guidance (4) are:
a) The excipients chosen, their concentration,
and the characteristics that can influence the
drug product performance (e.g. stability,
bioavailability) or manufacturability are
discussed. Compatibility of excipients with
other excipients, if relevant, should be
established. Excipient compatibility with
other excipients is specific to the
preservative. 
b) The intended functionality of the excipients
throughout the drug product shelf life
should be demonstrated. The excipients for
which the functionality should be
demonstrated are antioxidants, penetration
enhancers, disintegrants, and release
controlling agents.
c) The information on excipient performance
can be used to support the justification of
the drug product specification. 
d) Information to support the safety of
excipients, when appropriate, should be
cross referenced.
Formulations and process design protocols
must capture the above points. The
experimental trial outcomes are discussed in the
development report required for the CMC
review. Usually, drug substances and drug
product attributes and its manufacturability are
used to justify the appropriateness of excipient
selection. An understanding of pharmaceutical
hydrates as excipients and their impact on
product quality and its manufacturing process is
often helpful. Some of the commonly used
hydrates as excipients are, magnesium stearate,
lactose, glucose, dextrose or calcium
diphosphate. Use of magnesium stearates in the
solid dosage formulation is always critical.
Differences in the hydration state i.e., water of
crystallization between batches of magnesium
stearate impacts its lubrication properties (54).
The physical properties of magnesium stearate
vary between batches due to its hydration state
and thus affects powder beds mechanical
properties and tablet die wall friction. Physical
attributes, such as particle size, surface area,
porosity, surface morphology, and viscosity of
excipients have the potential to impact drug
product manufacturing process and quality
attributes. Sometimes commonly used
excipients such as, starch is modified by
chemical or mechanical methods to enhance its
functionality. For example, starch can be
modified chemically through carboxy-
methylation to enhance hydrophilicity and
crosslinking to reduce solubility. The source of
starch, particle size, amount of sodium chloride
(reaction by-product), viscosity, degree of
substitution and cross-linking effect the
functionality of the modified starch e.g.
pregelatizied starch, sodium starch glycolate etc.
The author has observed differences in
disintegration, and experienced capping during
compression due to differences in liquid uptake
and settling volume (15 versus 30) of
disintegrants e.g., Croscarmellose sodium. 
All possible excipients that could be used in the
proposed formulation are typically categorized
into soluble, insoluble, and hydrophobic
materials. The purpose is to ensure the quality
and robustness of the proposed formulation and
its manufacturability. For example, inorganic/
insoluble/hydrophobic excipients are generally
avoided in formulating BCS Class II and IV
drugs. Instead hydrophilic excipients together
with solubilizers/surfactants are chosen to
optimize dissolution and drug absorption. The
dissolution profile of the RLD and the
proposed drug product are frequently used to
rationalize the selection of the disintegrant and
control releasing agents used in the proposed
formulation. An example of excipient
description is described below.
Croscarmellose Sodium NF
Croscarmellose sodium NF is a crosslinked
polymer of carboxymethyl cellulose sodium





(NaCMC) and is an odorless, white or grayish
white powder. It is an anionic water insoluble
compound which is highly alkaline, and
hygroscopic in nature. The pKa of
Croscarmellose Sodium NF is 4.17. It swells to
4 to 8 times its original volume in contact with
water in less than 10 seconds. It has a bulk
density of 0.529 g/cc, and specific surface area
of 0.81–0.83 m2/g (55). 
In general, Croscarmellose Sodium NF is
nontoxic and nonirritant in nature. However,
oral consumption of large amounts of
Croscarmellose Sodium may have a laxative
effect, although the quantities used in solid
dosage formulations are unlikely to cause such a
problem. The reactive impurities present in
Croscarmellose Sodium are nitrite (NO2) and
nitrate (NO3). These reactive impurities can
react with functional groups, such as dialkyl,
alkylaryl, diaryl, cyclic secondary amines, N-
alkylureas, N-alkylcarbamates, and N-
alkylamides to form N-nitroso compounds (e.g.
nitrosamines or nitrosamides). The nitrosamines
or nitrosamides are the drug substance
degradates. Drug substance potency decreases
due to the formation of nitrosamines or
nitrosamides. In addition to the potency loss,
nitrosation at trace levels can also be
carcinogenic (56). Croscarmellose Sodium also
reacts with weakly basic drugs in the presence of
moisture causing loss in disintegration capacity.
Therefore, the ability of the disintegrant to fully
push apart the tablet matrix is reduced and
hence dissolution is slowed down. The change
in interparticulate bonding of the disintegrant is
believed to cause a decrease in dissolution rate.
Croscarmellose Sodium is not compatible with
strong acid or with soluble salts of irons and
other metals, such as aluminum, mercury, and
zinc. It loses its disintegration capacity when
used in wet granulation or in direct compression
with other hygroscopic ingredients e.g. sorbitol
(57). 
It is one of the so called super disintegrants and
used at a concentration up to 5% W/W of tablet
weight. The disintegration mechanism of
Croscarmellose Sodium is swelling and wicking.
It is suitable for both direct compression and
dry granulation. In addition to its disintegrant
property, the addition of a large amount of this
super disintegrant in the formulation of
micronized drugs prevents the agglomeration of
the drug substance during compression.
Risk assessment 
The ICH QbD Guidance requirements for risk
assessment of the input materials, as well as,
process parameters are summarized below (4):
a) Critical material attributes (CMAs) and
critical process parameters (CPPs) impacting
drug product CQAs is linked. 
b) Risk assessment is typically performed early
in the pharmaceutical development process
and repeated as more information becomes
available and greater knowledge is obtained.
The risk assessment tools mentioned in the
guidance are the Ishikawa (fishbone) diagram
and the failure mode and effects analysis
(FMEA).
c) Risk assessment could be based on prior
knowledge and initial experimental data.
The two basic elements of risk assessment are
the identification of hazards and evaluation of
risk associated with exposure to those hazards.
Three fundamental questions are often helpful
in defining risk. The questions are (i) what might
go wrong (ii) what is the likelihood (probability)
that it will go wrong and (iii) what are the
consequences (severity)? (8)
 
The CMAs of the drug substance are
determined considering the impact on the
biological properties (e.g. bioavailability), drug
product critical quality attributes and its
manufacturing process. The typical CMAs of
the drug substance for explicit tracking in risk





assessment are: polymorphism, particle size,
chemical reactivity, impurity, and water content. 
Generally, the drug product development report
describes the impacts of the drug substance
CMAs on drug product CQAs and its
manufacturability. A control strategy needs to
be outlined to control the identified CMAs of
the drug substance. An example of the
quantitative risk assessment is outlined in Table
4, considering the impacts of the drug substance
CMAs on drug product CQAs and its
manufacturability. A risk priority number (e.g.
low/medium/high) is used for the assessment.
PROCESS UNDERSTANDING 
The common elements of process
understanding are: (i) manufacturing process
selection, (ii) drug product and manufacturing
process development, and (iii) risk assessment. 
The elements of process understanding along
with the container and closures system are
discussed below.
Manufacturing process selection
The requirement is to select an appropriate
manufacturing process based on scientific
rationale. The purpose is to mitigate the
potential effects of the drug substance and
excipients attributes on drug product
performance as well as on unit operations.
Sometimes the manufacturing process of the
RLD is referred to justify the manufacturing
process selection of the proposed drug product.
The manufacturing process of the RLD could
be available in the literature or patents.
Sometimes reverse engineering study is also
performed to determine the manufacturing
process of the RLD. Some of the examples of
manufacturing process selection are: (i) since the
solubility of the drug substance is poor, a solid
dispersion/hot melt extrusion process is
employed to improve the dissolution and
absorption of the drug product, (ii) a dry/wet
granulation process is suitable when  the flow
property of the drug substance is poor;
however, dry granulation is  preferred for
reasons of  cost, (iii) a hot melt/wet granulation
process is selected as the drug substance shows 











Low: No investigation is required or not applicable
Medium: Investigation may be required
High: Investigation is required
DU: Uniformity of Dosages Unit
DT: Disintegration





reduced crystallinity after processing (e.g.
milling, micronization), (iv) a direct
compression/dry granulation process is selected
because the drug substance is susceptible to
hydrolytic degradation, and (v) encapsulation
approach is chosen as the drug substance has a
low melting point. Besides formulation
optimization, stringent environment and
process controls are required for any drug
substance susceptible to hydrolysis/
oxidation/photolytic degradations to ensure
desired drug product performance and its
manufacturability.
Drug product development
The ICH QbD Guidance requires an initial
formulation risk assessment to identify the
focus of the drug development. The goal is to
meet the QTPP. Formulation parameters, such
as pH dependent solubility of the drug
substance, drugs forming insoluble complexes
with the GI contents, instability in the GI tract,
and physicochemical interaction that could
affect in vivo absorption (58). In general, the drug
is micronized to increase the dissolution rate
and thereby the absorption of BCS Class II and
IV drugs. 
The micronized/fine particles have a large
specific surface  area and  hence dissolve at a
faster rate leading to improved drug absorption.
However, micronized/fine particles have a
greater tendency to form agglomerates which
can decrease the dissolution rate. Therefore, an
initial risk assessment of the proposed
formulation is performed to identify potential
problems that could affect the CQAs of the
drug (e.g. assay, dosage uniformity,
disintegration, dissolution, and impurities). The
typical ways to perform an initial formulation
risk assessment are a cause-and-effect diagram,
such as the Ishikawa (fishbone) diagram and
quantitative risk mapping. A risk priority
number, such as low, medium, or high is
employed for quantitative risk assessment.
Initial formulation risk assessments are often
based on prior information of the input
materials’ attributes together with knowledge of
developing similar dosage forms, as well as, the
unit operations. An example of an initial
formulation risk assessment is shown in Table 5.
The QbR requirements for the drug product
developments are: (i) what attributes the drug
product should possess, (ii) how the drug
product was designed to have these attributes,
(iii) how alternative formulations or
mechanisms were investigated, (iv) how the
excipients and their grades were selected, and (v)
how the final formulation was optimized. 
Table 5 Initial formulation risk assessment using prior knowledge
DP QA






















Low: No investigation is required or not applicable
Medium: Investigation may be required
High: Investigation is required






The required elements of the formulation
development as detailed in the ICH QbD
guidance (4) are:
a) The drug product CQAs is identified.
b) The evolution of the formulation design
from initial concept up to the final design
should be summarized.
c) The excipient ranges, if any, included in the
batch formula should be justified; this
justification can often be based on the
experience gained during development or
manufacture.
d) Formulations used in clinical safety and
efficacy and in any relevant bioavailability or
bioequivalence studies should be provided.
Any changes between the proposed
commercia l  formulat ion and the
formulation(s) used in pivotal clinical batches
and primary stability batches should be
clearly described and the rationale for the
changes provided.
e) Information from comparative in vitro studies
(e.g. dissolution) or comparative in vivo
studies (e.g. bioequivalence) that links clinical
formulations to the proposed commercial
formulation should be summarized and a
cross-reference to the studies (with study
numbers) should be provided. The results of
the in vitro/in vivo correlation (when
performed) and a cross-reference to the
studies (with study numbers), should be
provided.
f) Any special design features of the drug
product should be identified and a rationale
should be provided for their use. The special
design features include tablet score line,
overfill, and anti-counterfeiting measures.
Overages
a) Use of an overage of a drug substance is
discouraged. 
b) The information required for using an
overage are: (i) the amount of overage (ii) the
reason for the overage (e.g. to compensate
for expected and documented manufacturing
losses) and (iii) a justification for the amount
of overage.
c) The overage should be included in the batch
formula.
Typical formulation related deficiencies (59) are:
(i) Ethylcellulose is listed as a binder instead of a
rate controlling agent, provide data to
demonstrate that the amount of Ethylcellulose
used has no impact on the drug release profile,
(ii) it was concluded that high polymer content
can prevent the drug substance from
undergoing physical changes, such as re-
crystallization, clarify if the drug substance
remains as crystalline form or transforms to
amorphous form, (iii) provide the excipient
compatibility (chemical and physical changes)
study report performed during the
pharmaceutical development, and (iv) clarify the
difference in the acceptance criteria of the
excipient (name) between the vendor’s and
yours.
Therefore, the formulations and process design
protocol must integrate the QbD requirements
and the possible QbR deficiencies discussed
above. The findings are discussed in the
development report to expedite the CMC
review and to thereby reduce the approval time.
One of the main goals of formulation design is
to overcome the identified limitations of the
drug substance, such as poor solubility or
susceptibility to degradation. 
The solubility of some drugs is pH dependent,
and sometimes the drug has a tendency to
crystallize or precipitate during dissolution. For
example, dissolution of some weakly basic drugs
(e.g. Quetiapine Fumarate) slows down due to
its pH dependent solubility. The probable
reasons for this release problem are the variable





pH of the GI tract and/or precipitation or
crystallization of the free base during
dissolution. Sometimes the pH of the GI tract
increases as a result of antacid or food
consumption. The slow or incomplete drug
release impacts drug bioavailability/
bioequivalence. Therefore, the formulation is
often optimized to mitigate the described
degradation pathways of such drugs. The
common ways to improve the performance of
such drugs is to modify the micro-
environmental pH or to add an antioxidant in
the formulation to limit oxidative degradation.
Acidic excipients, such as Tartaric Acid/Citric
Acid/Fumaric Acid are often used in the
formulations of such drugs to overcome gastric
pH interaction. The addition of these excipients
in the formulation of such drugs ensures
optimal bioavailability/bioequivalence.
Therefore, the choice of pH modifying
excipients along with its levels for such drug is
critical.
Several formulations around the target are
usually examined through initial trials. The trials
are performed to determine the robustness and
sensitivity of the formulation and its impact on
drug product CQAs. In general, the formulation
variables are identified based on prior
knowledge and/or using the design of
experiment (DoE). The other typical
considerations for initial formulation design are
the patent on the drug substance, drug product
formulations, and its manufacturing process.
The common components of formulation
development are identification of lead
formulation, determination of excipient CMAs,
and risk assessment. These elements are
outlined below.
Identifying the lead formulation
In general, laboratory and pilot scale
experiments are performed to determine the
lead formulation(s). The quality attributes that
are examined during the lab scale trials are tablet
hardness and dissolution. The prospective
formulation(s) are determined based on the lab
scale trials. The prospective formulation(s) are
then scaled up to a 5 to 20 kg batch size or
more, depending on tablet weight and the
experimental design. Typical evaluations
performed at the pilot scale trials are: (i)
blending time and blender speed (ii) granulate
physical and chemical (blend uniformity) quality
attributes (iii) compression force and (iv) tablet
physical and quality attributes. The evaluations
of blend characteristics include particle size
distribution, bulk density (BD), tapped density
(TD), and blend uniformity of 6 or 10 locations
from the blender, and granules flowability. The
evaluations of the tablet physical attributes
include tablet weight (n=20), hardness,
thickness, and friability (6 g or more). The
quality attributes that are examined at this stage
are dosage uniformity (n=10 or 20), impurity
profile, and dissolution (n=12). Composite
samples from the beginning, middle, and end of
the operation are generally analyzed for
evaluation purpose.
The lead formulation(s) is often selected based
on tablet hardness, dosage uniformity, impurity
profile, and dissolution rate. Typically statistical
assessment is performed to compare the quality
attributes of the experimental batches and RLD.
One of the statistical assessments is to calculate
the p value.  The p values must > 0.05 to
demonstrate that quality attributes of the
experimental batches is comparable to the RLD.
Statistical analyses are performed to justify that
the proposed formulation is comparable to the
RLD.
The development report documents the
summary of each unit operations along with the
equipment and the process parameters used. It
also documents the in-process and quality
attributes obtained from all the trial batches.
The report identifies the processing problems
observed and the actions taken to overcome the
problems. This information is often useful for
investigating future deviations. The activities 





Table 6 Screening study
PATTERN DS* DILUENT 1 DILUENT 2 BINDER DISINTEGRANT LUBRICATION
1 ! ! ! ! + + -1 -1 -1 -1 +1 +1
2 ! ! + + ! ! -1 -1 +1 +1 -1 -1
3 ! + ! + ! + -1 +1 -1 +1 -1 +1
4 ! + + ! + ! -1 +1 +1 -1 +1 -1
5 000000 Target Target Target Target Target Target
6 + ! ! + + ! +1 -1 -1 +1 +1 -1
7 + ! + ! ! + +1 -1 +1 -1 -1 +1
8 + + ! ! ! ! +1 +1 -1 -1 -1 -1
9 + + + + + + +1 +1 +1 +1 +1 +1
*Theoretical low (-) and high (+) assay
performed at this stage are generally used to
justify formulation robustness and sensitivity.
Determining excipients CMAs
Excipient grade and level influence drug
product performance and its manufacturability.
Therefore, experimental trials are performed to
evaluate the impact of different grades and
levels of excipients on product quality and unit
operations. Experimental trials determine the
CMAs of the major excipients affecting drug
product performance and its manufacturability.
Prior knowledge of CMAs of the selected
excipients and manufacturing process in




Physical properties, for example, particle size,
loss on drying, and flow of different grades of
the same excipients are different. Formulations
are designed and performed using at least two
grades of the major excipients to evaluate the
impact on product quality attributes and its
manufacturability. The in-process quality
attributes that are examined during the trials
include weight (n = 20), hardness, thickness,
and friability (6 g or more), capping, cracking,
and disintegration. Dosage uniformity (n = 10),
the impurity profile, and dissolution (n= 6 or
12) are analyzed to evaluate the product
performance. The product development report
describes the impact of the excipient grades on
drug performance and its manufacturability.
The report is also expected to document
equipment and process parameters used for
each trial. The evaluated result is used to justify
the grades of the excipients.
Excipient Levels
Experimental trials are designed and performed
to assess the effect of the generally used
excipients, for example, diluent, binder,
disintegrant/solubilizer, glidant, and lubricant
levels on drug product in-process and quality
attributes and on unit operations. The
experimental trials are designed based on the
worst case scenario of the drug substance assay
(theoretical low and high assay values) or using
the design of experiment (DoE) model e.g.
screening study. In a worst case scenario, the
major excipient levels are calculated based on
the drug substance theoretical low and high
assay values. The other technique that can be
used is a screening study. An example of a
screening study based on low (-) and high (+)
levels of excipients is outlined in Table 6.
The summary report documents the trial
findings and describes the impact of excipient
levels on the drug product quality attributes
(physical and chemical). It also describes the
manufacturability of the drug and the
equipment and process parameters used. The
evaluated result justifies the excipient levels with
a target quantity that could be used in future. 






















The goal is to keep an option for continual
improvement.
Risk assessment
Chemical reactivity, excipient grades and levels
trials identify the risks of the CMAs on drug
product quality and its manufacturability.
Generally recognized CMAs of the excipients
for explicit tracking in risk assessments are
particle size, flow, hygroscopicity, and reactive
impurities. An example of assessing the risks of
formulation variables is described in Table 7.
The formulation development studies and the
risk assessment together determine the most
likely formulation that will ensure problem free
scale-up and subsequent process validation.
Therefore, the prospective formulation is used
during the manufacturing process development
study to finalize the ranges for the critical
process parameters of each unit operation. 
Manufacturing process development 
The elements of the manufacturing process
development as expressed in the ICH QbD
Guidance are listed below (4).
a) The selection, the control, and any
improvement of the manufacturing process
should be explained.
b) The selection of the manufacturing process,
appropriateness of the components and
equipment used should be discussed.
c) Critical process parameters are identified,
monitored and controlled.
d) Significant differences between the
manufacturing processes used to produce
batches for pivotal clinical trials (safety,
efficacy, bioavailability, and bioequivalence)
or primary stability studies and the process
for commercial manufacturing should be
discussed. The information should include,
for example, (i) identity (e.g. batch number)
and use of the batches produced (e.g.
bioequivalence study batch number), (ii)
manufacturing site, (iii) batch size, and (iv)
any significant equipment differences (e.g.
different design, operating principle, or size). 
e) A description of the measurement systems
applied during monitoring and collection of
CQAs/CMAs/ CPPs.  
f) An assessment of the ability of the process to
reliably produce a product of the intended
quality e.g. the performance of the
manufacturing process under different
operating conditions, at different scales, or
with different equipment.
The purposes of the manufacturing process
development are to (i) enable scale-up and
decrease variations in drug product quality and
its manufacturability using a science-based
approach, (ii) provide flexibility for future
process improvement, (iii) enhance process
understanding, (iv) to reduce risk through risk
assessment, and (v) justify the drug product
specification.
 





A manufacturing process development study for
non-problematic drug substances and
noncritical dosage forms is optional. For
example, an immediate release dosage form is
manufactured using a direct compression
process. The formulation contains a drug
substance that is highly soluble, stable, and
flows well. The other components, for example,
diluent, binder, disintegrant, and lubricant are
commonly used grades and are recognized in
the national formulary or other acceptable
quality standards. Their levels in the formulation
are supported by the the Inactive Ingredient
Database (IID) limits. The drug load in the
formulation is between >10% to <50% W/W. In
such cases, a manufacturing process
development study may not be required
provided that it could be justified based on prior
knowledge. 
Typical deficiencies pertaining to the
manufacturing process development (59) are (i)
to clarify how the critical process parameters
(CPPs) were identified, monitored, and/or
controlled for each unit operation, provide a
summary table to adds clarity and facilitates
review, (ii) drug content in the final blend is low,
the manufacturing process is a direct
compression process, provide available
information regarding the segregation potential
of the blend under your manufacturing
conditions, and the possible impact on the
content uniformity, (iii) for the pre-lubrication
and lubrication blending of the commercial
batch, establish your mixing time in relation to
the scale-up effect from a 5 cu. ft. to a 80 cu. ft.
blender, and (iv) provide data to justify your
tablet hardness range, especially its impact on
friability, shipping, and dissolution at the
extremes of the proposed hardness range.
A scale-up plan should be based on the risk
assessment of each variable and the process
understanding gained during pilot scale and
prior knowledge. One of the considerations for
scale-up manufacturing is the design and
operating principle of the equipment.  Special
attention is required if the manufacturing
equipment is not within the same SUPAC (scale
up and post approval changes) equipment class
of the bio or submission batch. The factors
considered in blending scale-up are (i) geometric
similarity: ratio of all lengths constant (constant
fill ratio), (ii) dynamic similarity: maintenance of
forces (Froude number), and (iii) kinematic
similarity: maintaining a consistent number or
revolutions. Experimental trials examine the
impacts of the process parameters of each unit
operations on drug product quality attributes
(in-process and CQAs) and its processability.
Trial findings determine the ranges of the
critical process parameters of each unit
operations. Identification of the CPPs of
different unit operations is summarized below.
 
Identifying the critical process parameters
(CPPs)
Typical CPPs of different unit operations and
their probable impact on the drug product in-
process quality attributes and CQAs, and the
drug’s manufacturability are discussed below.
 
De-agglomeration or milling
Screen size and impeller speed used during
milling can affect the drug substance (e.g. phase
conversion of metastable drugs) and the
segregation of low drug content formulation. In
general, smaller screen size and moderate
impeller speed is used to de-agglomerate the
cohesive/micronized drug substance. The
objective is to ensure uniform dispersion of the




Critical parameters of the blending process are
bin fill, mixing order, blending time, and blender
speed. The bin fill depends on several factors,
for example, (i) drug substance and excipients
flowability (ii) drug content in the formulation





and (iii) the manufacturing process. The bin fill
is especially critical for the direct compression
process which depends on drug content in the
formulation. The recommended bin fill for
mixing the cohesive/micronized/ fines and free
flowing drug substance and excipients is 60%
and 80% respectively of the blender working
capacity. A blend time analysis method is used
to evaluate blending time. Blend time analysis is
performed by collecting the blend sample from
the identified dead spots of the blender at
different time points. The collected blends are
usually examined for density, flow, blend
uniformity, compressibility, and dosage
uniformity.
Dry Granulation (Roller Compaction)
The purpose of compaction is to produce
quality granules to ensure optimum flow and
compressibility. Compaction process para-
meters control the physical quality attributes of
the granules, such as particle size and their
distribution, bulk and tapped density and flow.
Particle size and shape along with the density
influence the flow and compressibility of the
granules. Granules flow and compressibility
influence blend and dosage uniformity, and
compression force and speed, and thereby
impact drug product quality attributes, such as
tablet weight, hardness, friability, disintegration,
and dissolution. Generally recognized critical
parameters of the compaction process are
compaction force (CF), roller speed (RS), and
roller gap (RG). An example of identifying the
CPPs of the roller compaction process is
outlined in Table 8 using a partial factorial
design of experiment (DoE) model.
Table 8 Partial factorial DOE design: compaction
parameter evaluation
TRIALS PATTERN CF (kN/cm) – X1 RG (mm) – X2 RS (rpm) – X3
1 --+ -1 -1 +1
2 -+- -1 +1 -1
3 000 Target Target Target
4 +-- +1 -1 -1
5 +++ +1 +1 +1
The granule produced using each experimental
trial is analyzed for physical characterization.
The physical characteristics analyses determine
the compaction parameters as well as the in-
process acceptance limits of particle size
distribution (sieve analysis), density, and flow.
Compression
Typical critical parameters of the compression
process are compression speed and
compression force. In addition, sometimes
feeder speed may influence the segregation of
low drug content formulation leading to OOS
dosage uniformity and assay. Compression
speed influences blend flow and thereby impacts
tablet weight, hardness, and dosage uniformity.
Compression force influences tablet hardness,
disintegration, and dissolution. Trial plans, such
as low weight – high weight (LW – HW), low
speed – high speed (LS – HS) and low hardness
– high hardness (LH – HH) are designed and
performed to determine the ranges of the
compression parameters. The analysis of the
tablet physical quality attributes, for example,
weight, hardness, thickness, friability, and
disintegration of each experiment determines
the tablets in-process quality attributes along
with the compression speed. This also provides
a guideline for pre and main compression force.
Coating
There are two types, i.e., functional and non-
functional film coating. The degree of criticality
of the non-functional coating is less compared
to the functional coating. Sometimes, a seal coat
is applied based on the drug substance and the
coating solution/dispersion attributes. The
objective of a seal coat is to ensure the
robustness of the product. Triethyl citrate
(TEC) is commonly used as a plasticizer in
aqueous based delayed release coating. TEC is
slightly acidic in nature, and so can influence the
degradation of the drug substance (e.g.
Pantoprazole) during the coating process (60). 





Table 9 Delayed release coating process parameters
PARAMETERS RANGES CONTROLS COMMENTS
Coating Dispersion
Dry polymer on the tablet per cm2 area Yes Yes Ensure delayed release
Plasticizer on dry polymer Yes Yes Provides elasticity to polymer.
Total quantity of insoluble excipients Yes Yes Ensure film mechanical strength
Total solid contents Yes Yes Governs solidification, impacts film mechanical strength
Mixing time Yes Yes To ensure dispersion quality.
Coating Process
Pan Load Yes Yes Ranges based on study
Spray Rate Yes Yes Ranges based on study
Gun Distance No Yes Fixed for specific pan load
Gun Angle No Yes Fixed
Pan Speed Yes Yes Machine controlled in Auto Mode
Atomizing and Pattern Air Pressure No Yes Fixed based on study
Exhaust Air Temp. Yes Yes Based on study
Inlet Air Humidity Yes Yes Impact film mechanical strength of hygroscopic core.
High susceptibility to hydrolysis coupled with an
acidic environment influence the degradation. 
Therefore, a seal coat is applied to protect the
tablet core of such drug substances. In this case,
the seal coat does not contain TEC as a
plasticizer. The goal is to ensure that the reactive
ingredient, for example, TEC, in the final
coating formulation does not come into contact
with the core tablet. An example of identifying
the critical parameters of the delayed release
coating process is described in Table 9.
Worst case scenarios, e.g., extreme low and
extreme high together with risk assessments are
used to establish the ranges of the critical
process parameters of each unit operation.
Risk assessment: impact of the CPPs on DP
CQAs
The risk assessment tools for pharmaceutical
manufacturing process development are
described in the guidance (4, 8). They are failure
mode effects analysis (FMEA), failure mode
effects criticality analysis (FMECA), and hazard
operability analysis (HAZOP) (8). FMEA
focuses on how and when a system will fail, not
if it will fail. Regulatory bodies accept both
approaches, such as worst case experiments and
risk assessment tools to establish the CPPs and
their impact on CQAs. However, establishing
the critical process parameter ranges using a risk
assessment tool is optional for non-problematic
generic formulations and process development.
An example of determining the impact of
critical process parameter(s) of unit operations
on drug product CQAs is presented in Table 10
using FMEA risk assessment tool. 
The RPN and criticality number provides
guidance for ranking potentials failures in the
order they should be addressed.
Formulation and process selection
The formulation and manufacturing process
development studies determine the final
formulations and manufacturing processes for
the bioequivalence/stability/submission batch.
The drug product CQAs manufactured using
the optimized formulation and processes are
compared with the RLD.  The QbR questions
with respect to composition of the drug product
are: (i) what are the components and
composition of the final product and their
quality standard? What is the function of each
excipient, (ii) does any excipient exceed the
Inactive Ingredients Database (IID) limit for
this route of administration, and 
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5 1 5 25 5
Ranking
1 3 5 7
Severity (S) Low: Deviation Reprocessing Batch Rejected Recall
Occurrence (O) Unlikely: 1 out of 500 Occasional: 1 out of 100 
Repeated: 1 out
of 20 









Risk Priority Number  RPN = S*O*D,                              Criticality = S*O
(iii) do the differences between this formulation
and the reference listed drug (RLD) present
potential concerns with respect to therapeutic
equivalence? Therefore, the product and
process development  summary report describes
the (i) component and compositions of the final
product with reference to the quality standard
(ii) function(s) of each excipient (iii) excipient
levels with reference to the IID limit for the
route of administration (iv) potential differences
between the selected formulation and the RLD
with respect to therapeutic equivalence, if any,
and (v) comparative formulation of the
proposed drug product and the RLD.





Regulatory bodies accept the differences in
excipients  with a justification. An example of
component and composition, and a
comparative formulation of the proposed drug
product are presented in Tables 11 and 12
respectively.








STANDARDxx mg xy mg
DS X X1 -- Active
USP/BP/EP/
In-house
Excipient 1 X X2 -- Diluent NF/EP/ In-house
Excipient 2 X X3 -- Binder NF/EP/ In-house
Excipient 3 X X4 -- Disintegrant NF/EP/ In-house
Excipient 4 X X5 -- Glidant NF/EP/ In-house
Excipient 5 X X6 -- Lubricant NF/EP/ In-house
Tablet weight (mg) Xx xy





DS DS Active Diluent, binder and disintegrant
used in the proposed drug
product and RLD are different.
However, the diluent, binder
and disintegrant used in the
proposed drug product are
established and recognized for
solid dosages formulation. In
addition, the desired drug
product performance and its
manufacturability have been
established.
Excipient 1 Excipient x Diluent
Excipient 2 Excipient x Binder
Excipient 3 Excipient x Disintegrant
Excipient 4 Excipient x Glidant
Excipient 5 Excipient 5 Lubricant
Excipient 6 Diluent
x is used to differentiate material differences between the proposed
and RLD formulation.
Container and closures system
The ICH QbD Guidance requirements for the
container and closures systems are (4):
a) The choice and rationale for selection of the
container and closures system particularly the
primary packaging for the commercial
product are discussed. 
b) The choice of materials for primary
packaging should be justified. The discussion
should describe studies performed to
demonstrate the integrity of the container
and closure. 
c) The choice of primary packaging materials
should be considered e.g. choice of materials,
protection from moisture and light,
compatibility of the materials of construction
with the dosage form (including sorption to
container and leaching), and safety of
materials of construction. Justification for
secondary packaging materials should be
included when relevant.
The QbR questions related to the container
closures are: (i) rationale for choice of the
container closure system i.e. what specific
container closure attributes are necessary to
ensure product performance, (ii) what container
closure system(s) is proposed for packaging and
storage of the drug product? Has the container
closure system been qualified as safe for use
with this dosage form, and (iii) is the container
closures suitable for use with respect to
performance, functionality and safety. Relevant
compendial test and controls for the container
closure are USP <381> (Elastomeric Closures
for Injections), <87> (Biological Reactivity
Tests, In Vitro), <660> (Containers – Glass),
<661> (Containers- Plastics), and <671>
(Containers – Performance Testing). These
tests are intended to demonstrate the identity,
performance, suitability, compatibility and
safety of the container closures. Generally,
deficiency is cited, if this information is not
mentioned.
Environmental factors, such as moisture,
oxygen, and light often influence the
hydrolytic/oxidative/photo degradation of the
drug product. Therefore, the drug must be
protected by an effective barrier to prevent or
control the negative influence of environmental
factors. For example, the moisture ingress often
influences the appearance (e.g. discoloration)
and tablet softening or hardening as well as
hydrolytic degradation. Degradations adversely
affects assay; dissolution and impurity profile of





the drug product thereby compromising its
safety, purity and efficacy. Therefore, in general,
high humidity territories warrant extra
precautions.
A justification for the selection of the container
and closures system is required. Intrinsic
stability of the drug substance and distinctive
quality attributes of the primary packaging
component influence the selection of the
container and closures system. The quality
attributes of the container and closures are
physicochemical stability and barrier property
against environmental factors (e.g. moisture,
oxygen, and light). The other two aspects of
container and closures selection are its child
resistance property and security (e.g. anti-
counterfeiting, tamper evident). The child
resistance property of the container and
closures is a legal requirement for the USA and
Canada with few exceptions. However, child
resistance of the container and closures is not
mandatory in all European countries.  In some
European countries, the requirement is product
specific. In addition to protection against
environmental factors, the selection of the
container and closures system depends on the
cost of goods (CoGs), market trend, and
preferred pack size/patient compliance.
Selecting the right container and closures from
the beginning minimizes stability failure and
regulatory review questions. It also ensures the
best product shelf-life.
Stable products are not sensitive to
environmental factors. Therefore, the relevant
scientific data pertaining to the intrinsic stability
of the drug product and barrier property of the
container and closures are sufficient to show
the acceptability of the drug product’s
physicochemical integrity during storage.
However, for moisture/oxygen/light sensitive
drugs (e.g. Pantoprazole), it is required to
demonstrate that the container and closures
provide an effective barrier. Stability data at
different storage conditions supports the
effectiveness of the container and closures
barrier property.
The high density polyethylene (HDPE) bottle is
the preferred packaging format for tablets and
capsules in the USA and Canada. The most
common packaging for Europe and the rest of
the world (ROW) is blister. Understanding the
container and closures barrier properties and
the packaging processes provide the basis for
selecting the right container and closures. The
barrier properties of some commonly used
container and closures and typical critical
aspects of the packaging process are briefly
discussed below.
HDPE Bottle package
Water vapor transmission rate (WVTR) and
oxygen vapor transmission rate (OVTR)
influence the selection of the HDPE bottles.
Theoretical WVTR of a standard 60cc HDPE
bottle when stored at 40ºC/75% RH (relative
humidity) is equal to 1 mg of water per day.
Therefore, RH conditions within a standard
60cc HDPE bottle could re-equilibrate to 50%
within 1 day, even if a product is packaged
under low water vapor conditions. The OVTR
of the HDPE, Polypropylene (PP), and PVC
(polyvinyl chloride) bottle is 102 {g.mm/(
m2.day)}, 89 g.mm {g.mm/( m2.day)}, and 4
{g.mm/( m2.day)}, respectively. 
In addition to permeation through the walls, the
key vulnerability in a HDPE bottle is the screw-
topped closure even when a lid induction seal is
used. Moisture and oxygen levels in the
container head space can be significant enough
to affect the stability of some drugs. The author
experienced a decrease in the dissolution rate of
weakly basic drugs (e.g. Domperidone Maleate,
pKa of 13.4) in presence of Croscarmellose
Sodium NF due to the presence of
environmental moisture in the bottle head
space. Therefore, desiccants are used to prevent
moisture mediated degradations. The adsorb/
absorb capacity of the desiccant varies





depending on storage conditions. For example,
silica gel is efficient in absorbing moisture at
high RH, but inefficient at lower RH. However,
it is the opposite for molecular sieve desiccants.
The molecular sieve is approved for
pharmaceutical products in the EU, but not in
the USA for commercial products. The amount
of desiccant required to maintain relative
humidity within a specified range over the
product’s shelf-life can be calculated. The
calculation uses the WVTR of the container’s
material of construction and the rate of
moisture adsorbed by the desiccants. An
oxygen-impermeable seal (e.g., induction heat
seal) is used for oral solid dosage forms prone
to oxidative degradation. The induction seal is
also used to ensure security of the packaged
drug product. A secondary pack component can
augment light protection.
The opacity of the container does not
necessarily mean that it will protect the product
from light. HDPE bottles are generally
opacified with titanium dioxide pigment to
prevent light transmission. However, HDPE
bottles still allow significant light transmission
because the light is scattered both internally and
externally. Therefore, HDPE bottles are not
used to pack light sensitive drugs.
Blister packages
Three types of pharmaceutical blister package
are commonly used. They are: (i) thermoform
(ii) cold form and (iii) tropical blister. The two
components of a blister are forming/base film
and lid foil. The polymers influence the
characteristics of the commonly used blister
films and the critical aspects of the blister
packaging parameters. The intrinsic moisture
and oxygen transmission properties of
commonly used single polymers are different.
The intrinsic transmission rate is the
characteristic of each polymer (grade) and
represents the thickness independent barrier
performance (commonly called “the
transmission rate of a one micron thick film”).
PVC is the most commonly used base film in
blister packs. The WVTR of the PVC film of
250 microns is about 3.72 g/(m² d) at 38°C and
90% RH (61). The PVC film is commonly used
to pack stable drugs. The use of PVC in some
European countries is restricted by regulations
due to its disposal concern. The common
disposal method of PVC is incineration that
produces toxic gas.
Other blister films with superior barrier
properties are available on the market. Blister
films with enhanced barrier properties are
PVC/PVdC (po l yv iny l  d i ch lo r ide ) ,
PVC/PCTFE (polychlorotrifluroethylene), and
cold form.
For PVdC coated PVC film, PVdC layer is
specified in gsm. The weights of commonly
used PVdC coating are 40 gsm, 60 gsm, 90 gsm,
and 120 gsm. The PVC/PVdC film is offered
with or without a middle layer of polyethylene
(25µ PE). The polyethylene is used with a
heavier coating of 60 gsm, 90 gsm or 120 gsm
to improve the thermoforming characteristics
of the blister cavity. The PVC/PVdC coated
film provides medium to high barrier
protection. Depending on the weights of PVdC
coating, the WVTR of the PVC/PVdC coated
film is varied between 0.6 g/(m²d) to 0.2
g/(m²d) at 38°C and 90% RH (62). PVC/PVdC
coated films are easy to form, but PVdC tends
to release gas during blister forming. The
released gas is sticky in nature and is also
reported to damage the blister formats (63).
Depending on the thickness of the PCTFE
film, the WVTR of the PVC/PCTFE film is
between 0.05 g/(m²d) to 0.45  g/(m²d) at 38°C
and 90% RH. Generally, sustained/controlled
release products and rapidly dissolving drugs
are packaged using PVC/PCTFE blister film.
The draft angle of the blister mold for
PVC/PCTFE film is generally designed to be 5°
to avoid non-uniform blister formation. A plug
assist is required if blister depth is >6 mm to





avoid malformation. The most common
problem of the PCTFE film is the curl
formation towards the PCTFE side of the
blister. Therefore, during the blistering process
low heat is applied to the PCTFE side to
minimize curl formation.
The product contact requirements for
PVC/PVdC and PVC/PCTFF are different for
the USA and Europe. In the USA, the product
contact may only br PVC whereas either PVC
or PVdC is acceptable in Europe.
Commonly used lid foils are hard aluminum,
soft aluminum, paper/aluminum, paper/PET/
aluminum. Hard aluminum is the most widely
used push-through lid foil in Europe.
Paper/PET/aluminum is predominantly used
in the USA for peel-push (child resistant)
blister. The product contact requirement for lid
foil is that the heat seal lacquer must be non-
reactive and non-toxic. The heat seal lacquer
non-reactive and non-toxic information is
available in the open part of the DMF.
The cold form blister provides a nearly absolute
barrier against moisture, oxygen, and light. The
cold form blister generally contains three layers.
These are (i) OPA (oriented polyamide)/
aluminum/PVC (ii) OPA/aluminum/nylon and
(iii) OPA/aluminum/PP. The presence of
aluminum in the cold form blister ensures best
protection from light. Cold form blister
materials are mostly used to pack drug products
that are extremely sensitive to moisture, oxygen,
or light.
Some other critical aspects of blister packaging
are: (i) blister tip thickness, (ii) sealing
temperature, and (iii) outer seal width. The
preferred blister tip thickness is one fourth of
the base film original thickness. However for
stable products, the tip thickness could be up to
one sixth   of the original thickness. An outer
seal width of 3 mm is optimum for
moisture/oxygen sensitive products. Generally,
a channel is formed between the lid foil and
base films due to overheating during sealing.
The formed channel allows water/oxygen vapor
to pass into the blister pockets, which facilitates
the degradation of the drug product. Therefore,
the sealing temperature is controlled to ensure
optimum sealing, which is generally tested by
performing a leak test.
 
The appropriate container and closures are
selected based on the primary packaging
materials quality attributes and the drug
substance intrinsic stability. The developed drug
products are packaged using the selected
container and closures. The packaged product is
then placed in stability following the ICH
stability guideline (44, 64). The product placed
in stability is then analyzed at different intervals
to assess the integrity, safety, and purity of the
drug product. The data is also used to
demonstrate the suitability of the container and
closures.
 
The science based analysis of the drug
substance attributes, drug product formulation
and manufacturing process, and the packaging
components discussed above provide the
highest confidence for product integrity.
CONTROL STRATEGY
The ICH QbD Guidance requires the design of
control strategy to ensure consistent quality of
the drug product. The elements of control
strategy should describe and justify how in-
process controls and the controls of input
materials e.g., drug substance and excipients,
intermediates e.g., in-process materials,
container and closure system, and drug product
contributes to final product quality. A control
strategy can include, but is not limited to, the
following as outlined in the Guidance (4).
a) Control of input material attributes (e.g. drug
substance, excipients, primary packaging
materials) based on an understanding of their
impact on processability or product quality;






c) Controls for unit operations that have an
impact on downstream processing or
product quality (e.g. the impact of drying on
degradation, particle size distribution of the
granulate on dissolution);
d) In-process or real-time release testing in lieu
of end-product testing, for example,
analyzing CQAs (blend and dosage
uniformity) during processing;
e) A monitoring program (e.g. full product
testing at regular intervals) for verifying
multivariate prediction models.
Control strategy pertaining to the test method
and testing frequency of the input materials is
out of the scope of this paper. Control strategy
for the input materials, unit operations, and
drug product is briefly discussed below.
Drug substance
The control strategy for a drug substance is
determined based on the risk assessment
pertaining to intrinsic stability, particle size,
impurity, chemical reactivity, and their impact
on drug product CQAs as well as its
manufacturability. For example, sometimes, the
oxidative degradates (>1%) derived from the
drug substance are controlled to prevent or
minimize the impact on drug product quality.
The ways to control the oxidative degradates
(>1%) of the drug substance and their
interact ion wi th  peroxides  and/or
environmental factors are discussed below.
% Set a tighter limit for the oxidative degradates
derived from the drug substance and the
reactive impurities of the excipient based on
the annual rate of change.
% Perform real time analysis (i.e. prior to use)
of the excipient containing reactive impurity.
% Add Butylated hydroxyanisole (BHA),
Buty la ted  hydroxyto luene (BHT),
Ethylenediaminetetraacetic acid (EDTA),
Ascorbic acid, Thioglycerol, Propyl gallate in
the formulation.
% Introduce an antioxidant (e.g. BHA or
Tetrahydrofuran (THF)) as an impurity in
the drug substance, if possible.
% Assign hold time for each unit operations to
limit the exposure to environmental oxygen,
moisture and temperature.
% Ensure minimum head space in the bottle by
selecting the right size bottle for each count
and use of desiccant.
The controls discussed above are generally
included either in the master production
document or in the release testing specification
as appropriate. In general, drug specific tests
(e.g. polymorphism, particle size, optical
rotation, water content, impurities, and residual
solvent) are captured in the control strategy.
The typical control strategy for stabilizing photo
labile degradation is the addition of light
absorbing agents, such as pigments, colorants,
or UV absorbers in the formulation or use of
appropriate packaging components. The
effectivity of the light absorbing agents are
pigments > colorants > UV absorbers. The
ideal packaging component for extreme photo
labile drugs is aluminum foil.
Excipients
The specifications for excipients are included
USP/NF compendial monographs. Sometimes,
additional specifications, such as particle size
and viscosity are included in the release testing
to control excipients with critical functional
roles or specific grades (e.g. povidone, guar
gum). For non-compendial excipients, the
development report must provide a description
of the tests performed to control identity and
quality along with the validation of the test
method. Special attention is given to control
and monitor the reactive impurities of the





excipients to ensure the product purity, safety
and efficacy.
Drug product
Usually the drug product specification includes
the tests, procedures, and acceptance criteria
used to control quality, identity, strength, and
purity of the drug product.
 
The risk assessments are usually the basis for
the control strategy. An example of determining
the control strategy for input materials and unit
operations using risk assessment and mitigating
the risks is outlined in Table 13.
PRIOR KNOWLEDGE
Prior knowledge is one of the important
elements of the QbD approach, which is
generally the starting point for subsequent
assessment. Prior knowledge could be used
during the risk assessment  of the drug
substance, excipient selection, formulation and
process design. However, it cannot be
generalized as a standard set of information for
all applications. It is relevant to the submission
if it (i) clearly delineates similarities and
differences, (ii) properly links CQA’s with
CMA’s and CPP’s, (iii) justifiable/qualifiable
based on scientific rationale, (iv) supported by
relevant data, and (v) can fill the gaps/missing-
links, as applicable. Outside information and
industry or in-house information could be used
as prior knowledge. The typical sources of
outside information are: published literature,
r e s e a r c h  a r t i c l e s ,  r e v i e w  p a p e r s ,
patents/intellectual properties, reference books,
RLD label, and suppliers (equipment/material)
technical data sheets. The pertaining industry or
in-house information are capability (equipment
and technology available, process know-how),
dosage form/drug delivery system specific prior
submissions, dosage form/drug delivery system
specific expertise, specialized material
attributes/utilization expertise, drug product
specific expertise, and policies/procedures in
place. An example to justify the use of prior
knowledge is provided in Table 14.
CONCLUSION
There are challenges in implementing QbD and
QbR when developing formulations and
processes for generic drugs. However, there are
benefits when adopting QbD, for example it is
possible to select the optimum formulations
and processes with a reasonable confidence.
Building in QbD to the development process 
minimizes answers to  regulatory review
questions and hence, first cycle approval. It can 
reduce the time for preparing common
technical documents (CTD) and also reduce
overall product and process development costs.
Finally, it will allow for continuing
improvements throughout the product life-
cycle. The application of QbD minimizes the
risks of failing bioequivalence studies, scale-up,
validation, and stability studies. It is required to
spend considerable time during the product and
process characterization phase compared to the
execution of the trials. The key to making QbD
and QbR implementation a success is the
app rop r i a t e  p roduc t  and  p roce s s
characterization based on sound scientific
principles together with risk assessment. The
other  requ i rements  for  success fu l
implementation of the approach are a strong
commitment by top management, appropriate
planning, and focused project management.
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Chemical Name A C NA
Polymorphism Do not exist Do not exist Similar
Chiral Center None None Similar
BCS Class/Solubility
Class I, Soluble at pH 1.2 to
7.5 
Class I, Soluble at pH 1.2 to
7.5
Similar
pKa 6.0 7.0 Similar







Water Content LT 2.0% LT2.5% Comparable
FORMULATION
Drug Content 15 %W/W 20 %
W/W Comparable









Content 5% W/W 4%
 W/W
Major Diluent and Binder
Ratio
3:2 2:1 Comparable
Glidant 0.5% W/W 0.8%
 W/W Comparable
Lubricant 2.0% 1.8% Comparable
MANUFACTURING 
Batch Size 300 kg 280 kg Within ± 10%
Process Dry Granulation Dry Granulation Same
Pre-blending time 15 minutes 12 minutes Comparable
Final blending time 5 minutes 5 minutes Same
In-process criteria
Tablet shape Modified Caplet Caplet Similar
Tablet weight 220 mg 200 mg Comparable
Tablet hardness 10 – 18 kp 8 – 16 kp Similar
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